Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.42 |
| ▸ | DPYD | Q12882 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 9/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069636 | 0.86 | DPYD (0.42) | NEK1DPYDIMPDH2IMPDH1MCL1 | |
| SCHEMBL5241735 | 0.73 | PARP1 (0.42) | NEK1KDM4EALDH1A1PDPK1PARP1 | |
| SCHEMBL3997640 | 0.72 | DPYD (0.38) | NEK1DPYDIMPDH2IMPDH1MCL1 | |
| SCHEMBL3359768 | 0.72 | IMPDH2 (0.41) | NEK1DPYDIMPDH2IMPDH1MCL1 | |
| SCHEMBL19631236 | 0.71 | NEK1 (0.37) | NEK1IMPDH2IMPDH1KDM4EALDH1A1 | |
| SCHEMBL11025589 | 0.71 | IMPDH2 (0.60) | DPYDIMPDH2IMPDH1MCL1KDM4E | |
| SCHEMBL29196577 | 0.70 | KDM4E (0.53) | KDM4EALDH1A1PDPK1PARP1DYRK1A | |
| SCHEMBL3086572 | 0.70 | DPYD (0.40) | DPYDIMPDH2IMPDH1MCL1KDM4E | |
| SCHEMBL32666747 | 0.68 | PARP1 (0.38) | NEK1KDM4EALDH1A1PDPK1PARP1 | |
| SCHEMBL389138 | 0.66 | PARP1 (0.41) | NEK1MCL1ALDH1A1PDPK1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100226917-A1 | METHODS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| EP-2144630-A2 | CHK1 INHIBITORS WITH B CELL DEPLETING ANTIBODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | AstraZeneca AB (SE) | 2010-01-20 | — | — | EP | disclosed |
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| WO-2008132500-A2 | CHKL INHIBITORS WITH B CELL DEPLETING ANTIBODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1869052-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006106326-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | CHEK1, PDK1, CHEK2 | NEK1 212/4885DPYD 511/4885IMPDH2 1339/4885 |
| US-20100226917-A1 | METHODS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | CHEK1, CHEK2, MCL1 | NEK1 541/4885DPYD 1773/4885IMPDH2 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.